STATISTICAL ANALYSIS PLAN
FOR CLINICAL STUDY REPOR T
A PHASE 2, PLACEBO C ONTROLLED, RANDOMIZE D, DOUBLE -BLIND, 
PARALLEL -ARM STUDY TO EVALUAT E EFFICACY AND SAFET Y OF BMS -986141 
FOR THE PREVENTION O F RECURRENT BRAIN IN FARCTION IN SUBJECTS
RECEIVING ACETYLSALI CYLIC ACID (ASA) FOL LOWING ACUTE ISCHEMI C 
STROKE OR TRANSIENT ISCHEMIC A TTACK
PROTOCOL (S)CV006004
VERSION #1.0
1.0
Approved
930113650
1.0
v
Statistical Analysis Plan CV006004
BMS -986141 par4
2TABLE OF CONTENTS
STATISTICAL ANALYSIS PLAN FOR CLINICAL ST UDY REPORT ................................... 1
TABLE OF CONTENTS ............................................................................................................ 2
LIST OF TABLES ...................................................................................................................... 5
LIST OF FIGURES .................................................................................................................... 6
1 BACKGROUND AND RATIO NALE ...................................................................... 7
2 STUDY DESCRIPTION .......................................................................................... 8
2.1 Study  Design ............................................................................................................ 8
2.2 Treatment Assignment .............................................................................................. 9
2.3 Blinding and Unblinding ......................................................................................... 10
2.3.1 Blinding .................................................................................................................. 10
2.3.2 Unblinding ............................................................................................................. 11
2.4 Protocol  Amendments ............................................................................................. 11
3 OBJECTIVES ........................................................................................................ 11
3.1 Primary ................................................................................................................... 11
3.2 Secondary ............................................................................................................... 11
3.3 Safety..................................................................................................................... 12
3.4 Exploratory ............................................................................................................. 12
4 ENDPOINTS .......................................................................................................... 12
4.1 Primary Efficacy  Endpoint ...................................................................................... 12
4.1.1 Symptomatic Stroke ................................................................................................ 12
4.1.2 Unrecognized Brain Infarction ............................................................................... 13
4.2 Secondary  Efficacy  Endpoints ................................................................................ 13
4.3 Exploratory  Endpo ints............................................................................................ 13
4.4 Primary Safet y Endpo int......................................................................................... 14
4.5 Addit ional Safet y Endpo ints................................................................................... 14
5 SAMPLE SIZE AND POWE R............................................................................... 14
6 STUDY PERIODS, TREAT MENT REGIMENS AND PO PULATIONS 
FOR ANALYSES .................................................................................................. 15
6.1 Study  Periods.......................................................................................................... 15
6.2 Treatment Regimens ............................................................................................... 15
6.3 Popul ations for Analyses ........................................................................................ 15
7 STATISTICAL ANALYSES .................................................................................. 16
1.0
Approved
930113650
1.0
v
Statistical Analysis Plan CV006004
BMS -986141 par4
37.1 General Methods .................................................................................................... 16
7.1.1 General Methods for Study Periods ........................................................................ 16
7.1.2 General Methods for Efficacy Analyses ................................................................... 17
7.2 Study  Conduct ........................................................................................................ 19
7.2.1 Accrual ................................................................................................................... 19
7.2.2 Relevant Protocol Deviations .................................................................................. 19
7.3 Study  Popul ation.................................................................................................... 20
7.3.1 Subject Disposition ................................................................................................. 20
7.3.2 Demographic and Baseline Characteristics ............................................................ 20
7.3.3 Medical History ...................................................................................................... 21
7.4 Extent of Exposure ................................................................................................. 21
7.4.1 Administration of Study Therapy ............................................................................. 21
7.4.2 Study Therapy Compliance ..................................................................................... 21
7.4.3 Modifications of Study Therapy .............................................................................. 22
7.4.4 Concomitant Medications ....................................................................................... 22
7.5 Efficacy .................................................................................................................. 22
7.5.1 Primary Efficacy Analysis ....................................................................................... 22
7.5.1.1 Sensitivity Analyses ................................................................................................. 23
7.5.1.2 Subgroup Analyses ................................................................................................. 23
7.5.2 Secondary Efficacy Analyses ................................................................................... 24
7.5.3 Other Efficacy Analyses .......................................................................................... 25
7.6 Safety Analyses ...................................................................................................... 25
7.6.1 Major Bleeding and Clinically Relevant Non -Major Bleeding ................................. 25
7.6.2 Deaths .................................................................................................................... 26
7.6.3 Serious Adverse Events ........................................................................................... 26
7.6.4 Adverse Events ....................................................................................................... 26
7.6.5 Clinical Laboratory Evaluations ............................................................................. 27
7.6.6 Electrocardiograms ................................................................................................ 28
7.6.7 Vital Signs .............................................................................................................. 28
7.6.8 Physical Examination Findings ............................................................................... 29
7.7 Pharmacokinet ic Analyses ...................................................................................... 29
7.8 Biomarker Analyses ............................................................................................... 29
8 CONVENTIONS .................................................................................................... 30
1.0
Approved
930113650
1.0
v
Statistical Analysis Plan CV006004
BMS -986141 par4
48.1 Decimal Places ....................................................................................................... 30
8.2 Pharmacokinet ic Summaries ................................................................................... 30
8.3 Day Ranges for Analysis of Time Points ................................................................. 30
8.4 Multiple Measurements .......................................................................................... 31
9 CONTENT OF REPORTS ..................................................................................... 32
APPENDIX 1 MARKED ABNORMALITY C RITERIA FOR LABORATO RY 
TEST RESULTS -CONV ENTIONAL (US) UNITS .............................. 33
APPENDIX 2 MARKED ABNORMALITY C RITERIA FOR LABORATO RY 
TEST RESULTS --SI UNITS ................................................................ 37
10 REFERENCES ....................................................................................................... 41
1.0
Approved
930113650
1.0
v
Statistical Analysis Plan CV006004
BMS -986141 par4
5LIST OF TABLES
Table 5-1: Randomization Targets ........................................................................... 14
Table 7.2.2 -1: List of Relevant Protocol Deviat ions...................................................... 19
Table 7.4.1 -1: Extent of Exposure Categories for Summarizat ion.................................. 21
Table 7.5.1.2 -1: Subgroups of Interest for Efficacy Assessments ...................................... 23
Table 7.6.7 -1: Out of Range Vital Signs Criteria ........................................................... 29
Table 8.3 -1: Analysis Windows for Laboratory  Parameters & Vital Signs (Part 
1)............................................................................................................ 31
Table 8.3 -2: Analysis Windows for Laboratory  Parameters & Vital Signs (Part 
2)............................................................................................................ 31
Table 8.3 -3: Analysis Windows for ECG Results ....................................................... 31
1.0
Approved
930113650
1.0
v
Statistical Analysis Plan CV006004
BMS -986141 par4
6LIST OF FIGURES
Figure 2.1 -1: Study  Design Schemat ic for Part 1 ............................................................ 9
Figure 2.1 -2: Study  Design Schemat ic for Part 2 ............................................................ 9
1.0
Approved
930113650
1.0
v
Statistical Analysis Plan CV006004
BMS -986141 par4
71 BACKGROUND AND RATIO NALE
 
 
 
 
 
 
 
1.0
Approved
930113650
1.0
v

Statistical Analysis Plan CV006004
BMS -986141 par4
8.
Research Hypothesis:  
BMS -986141 is effect ive in reducing the recurrence of stroke in subjects with recent TIA or
stroke.
Schedule of Analyses:
No interim analyses are planned to assess efficacy.  The DMC will, however, review safety data 
after 10% of the total planned subjects for the study (approximately 132 subjects) have been 
rando mized and have co mpleted thei r scheduled Day  28 visi t.  Additionally, pharmacokinet ics of 
BMS -986141 will be expl ored to assess exposures and potenti al relati onship to safety .  There are 
no other pl anned interim analyses for this study . 
The final analyses for the clinical study report will be performed following the database lock 
after all subjects have co mpleted the study .
2 STUDY DESCRIPTION
2.1 Study Design
This study is a rando mized, double -blind, placebo -controll ed, parallel arm clinical trial in 
subjects receiving acetylsalicylic acid (ASA) with a recent Acute Ischemic Stroke (AIS) or 
Transient Ischemic Attack (TIA).
The study consists of two parts.  Part 1 will have a treatment duration of 28 days.  Part 2 will 
begin once resul ts from ongoing toxicology studies are reviewed, and will have a treatm ent 
period of  90 days.  Subjects enrolling in Part 1 will not be all owed in Part 2.  The figures below 
illustrate the treatment plan for both study  parts.
1.0
Approved
930113650
1.0
v

Statistical Analysis Plan CV006004
BMS -986141 par4
9Figure 2.1 -1: Study Design Schematic for Part 1
Figure 2.1 -2: Study Design Schematic for Part 2
2.2 Treatment Assignment
At the screening visit each subject will be assigned a unique sequent ial subject number by the
Interactive Voice Response System  (IVRS). The subjec t number will consist of 5 digits whic h
are assigned sequent ially (00001, 00002, 00003, etc.) by  the IVRS. Thi s number will be used for
1.0
Approved
930113650
1.0
v
Statistical Analysis Plan CV006004
BMS -986141 par4
10ident ificat ion throughout the study  and will not be used for any other participant. Screening of
subjects wi th lacunar i nfarcts will be capped at approximately  20%.
In addit ion to the two Parts of the study  noted above, which are related to treatm ent durati on, the 
study also consists of two phase s, each with a slight ly different method of assigning study 
treatm ent.  InPhase A, subjects will be randomized 1:1:1 using IVRS to one of twodoses of 
BMS -986141 (0.8 mg or 4.8 mg) or placebo.  In Phase B, subjects will be rando mized 1:1:1:1 
via IVRS to one of three doses of BMS-986141 (0.8 mg, 4.8 mg, or 8 mg) or placebo .  The 
transi tion from Phase Ato Phase Bof the study will only occur after an Independent Data 
Moni toring Commit tee (DMC) has reviewed data from the first 10% of the planned subjects 
(approximately 132 subjects wit h 28 days of data). As o f the time of  the wri ting of this SAP, the 
decisio n to move from Part 1 to Pa rt 2 of the study has been made.  Some sites will continue to 
enroll subjects in to Part 1 of  the study  until Part 2 can be fully implemented.  As a resul t, there 
will be no subjects rando mized in Phas e B during Part 1 of the study .
Randomization schedules will be generated by BMS and kept by the IVRS vendor.   All subjects 
will receive open -label ASA at a dose from 75 to 162 m g per day beginning at a time consistent 
with local standards of care for patients with AIS or TIA.  As mentioned in section 2.1
, the 
planned study  dosing durati on is 28 days for Part 1 of the study  and 90 days for Part 2 of the 
study .
At all study visits when study  drug is dispensed, each subject will be assigned a container
number by the IVRS. Container numbers will be assigned non-sequent ially and will correspond
to th e numbers printed on the packages and bottles containing study  drug, and will be recorded
on the appropriate eCRF. The IVRS will be available 24 hours per day , 7 day s a week.
2.3 Blinding and Unblinding
2.3.1 Blinding
Blinding o f treatm ent assi gnment is cri tical to the integri ty of this clinical study . However, in the 
event of a medical emergency or pregnancy in an individual subject in which knowl edge of the 
investigat ional product is critical to the subject’s management, procedures are in place to have 
the blind broken for an individual subject.
Except as noted, BMS Research and Devel opment personnel, as well as all vendors responsible
for the conduct of the trial (protocol  team) will remain blinded for the durati on of the trial. The
Data Moni toring Commi ttee (DMC) will assess safety  on an ongoing basis, and will have access
to unblinded treatm ent codes. An analysis team , including a reporti ng statistician and
programming supp ort, who are not involved wi th the conduct of  the study , will provide analyses
to the DMC. This unblinded analysis team  will not provide any informat ion from unblinded
analyses to the protocol team until after the trial has been co mpleted.
The Bioanaly tical Sciences section or its designate will be unblinded to the rando mized
treatm ent assignments in order to minimize unnecessary analysis of sam ples from control  group
subjects. Likewise, the Biotransformati on section or its designate may be unblinded, if
1.0
Approved
930113650
1.0
v
Statistical Analysis Plan CV006004
BMS -986141 par4
11metabo lite profiling work is conducted. This unblinded analysis team  will not provide any
inform ation from unblinded analyses to the protocol team unt il after the trial has been completed.
Platelet aggregati on data will be collected and reviewed for QC pur
poses by hospi tal and vendor
personnel not associ ated with the clinical conduct of the study . During the double -blind
treatm ent period, platelet aggregation will be masked to the Invest igator and protocol  team . One
biomarker representative, may be unmasked to review the platel et aggregati on data, and will not
provi de any informat ion that can potenti ally be unblinding to the protocol  team until after the
trial completes. The unmasked platelet aggregation data will be provi ded to th e study  team  after
the trialhas been co mpleted.   
2.3.2 Unblinding
For this study , the method of unblinding for emergency purposes is IVRS.   Details are included 
in the IVRS manual.
2.4 Protocol Amendments
A protocol  revision was formally issued on 07- July-2016, incorporating several design changes
into the study .  Most n otably , the original planned high dose of BMS-
986141 was reduced from 
16 m g to 8 m g, and this arm  of the study  is to be cl osed off until  the Data Moni toring Commi ttee 
is able to ev aluate sufficient safet y data from the 2 lower dose groups (0.8 mg and 4.8 mg).  To 
that effect, the randomizat ion scheme was updated to keep the 8mg arm closed until the DMC 
convened.  Pending the outcom e of the DMC meet ing, the 8mg arm would open and 
rando mizat ion woul d proceed in a 1:1:1:1 fashionfrom there forward to on e of the three BMS -
986141 doses or placebo (see Table 5 -1).
Addit ional updates were made to clarify various aspects of the study  and can be found in the 
protocol  revisi on.  No f urther updates had a significant impact to the statistical methods planned 
for this study .
3 OBJECTIVES
3.1 Primary
The primary objective of the study  is to determine the dose-response relationship of BMS -
986141 
on the recurrence of brain infarct ion at 28 days as assessed by a composite of 
symptom atic ischemic stroke andunrecognized brain infarct ion as assessed by MRI in subjects 
with ischemic stroke or TIA treated with ASA .
3.2 Secondary
To assess the effect of BMS-986141 on the occurrence of major adverse cardi ovascular 
events (MACE, including all stroke, myocardial infarction, and CV death) by  Day 90
To assess the effect of BMS-986141 on the occurrence of the composit e of ischemic stroke, 
myocardial  infarct ion, and CV death by Day 90
To assess the effect of BMS-986141 on incidence of symptomat ic recurrent ischemic stroke 
up to 28 day s of treatment
1.0
Approved
930113650
1.0
v
Statistical Analysis Plan CV006004
BMS -986141 par4
12To assess the effect of BMS-986141 on the occurrence of the composite ofunrecognized 
brain infarct ion assessed by MRI at Day  28 and MACE by Day 90
3.3 Safety
To assess the effect of BMS -986141 on the composite of Major and Clinically Relevant Non -
Major (CRNM) Bl eeding
To assess the effect of BMS -986141 on all reported bleeding
Toevaluate safety and tolerabilit y of BMS -986141
3.4 Exploratory
  
 
 
 
 
 
 
 
4 ENDPOINTS
4.1 Primary Efficacy Endpoint
The primary efficacy endpo int of the study is the incidence of a  composite of symptomatic
ischemic stroke by Day 28 and unrecognized brain infarct ion assessed by MRI at Day 28.  Each 
of these will be assessed by an adjudicati on committee.   If a subject experiences any of these 
events, the subject will be counted as having experience da com posite event in the analysis.
In the event that one, but not both of the components of the primary endpo int cannot be 
ascert ained, then the remaining component will be evaluated.  In this case, if the remaining 
component is counted as an event, the composite event will be considered as having occurred.  
If, however, the remaining component is not counted as an event, or if both of the com ponents of 
the primary endpoint cannot be ascertained, the resul ting primary endpoint will be considered as 
missing.
4.1.1 Symptomatic Stroke
All cases of suspected recurrent stroke will be adjudicated by a blinded Clinical Events
Adjudicat ion Commit tee (CEC). Diagnosis of stroke will require the abrupt onset of focal 
1.0
Approved
930113650
1.0
v

Statistical Analysis Plan CV006004
BMS -986141 par4
13neuro logical symptom s lasting at least 24 hours. Evaluat ion and treatm ent of strokes will be 
according to the local standard of care. It isstrongly recommended (but not required) that an
imaging procedure such as a CT scan or MRI be performed to evaluate events of suspected 
stroke or TIA. 
Adjudicated strokes will becategori zed by the CEC as defini te ischemic, defini te hemorrhagic, 
hemorrhagic transform ationor type uncertain. Addi tional classificat ion of stroke subtypes will 
be specified in the CEC charter.
4.1.2 Unrecognized Brain Infarction
MRI of the brain will be obtained in all subjects no later than within 24 hours of rando mizat ion
and at the Day 28visit. The baseline and Day 28MRIs for each subject will be reviewed 
independent ly by the blinded neuroradi ologists of the Imaging Adj udicati on Commi ttee(IAC) to 
determine if any new areas of infarct ion have developed since the baseline MRI. These 
independent assessments will undergo adjud ication according tothe processes described in the 
Imaging Charter with a single, adjudicated determinat ion recorded for each subject.
4.2 Secondary Efficacy Endpoints
Secondary  endpoints include:
The incidence of Major Adverse Cardiovascular Events (MACE) byDay 90, defined as a 
composite of adjudicated recurrent stroke, myocardi al infarct ion, or cardiovascular -related 
death (CV death)
The incidence of a co mposite of adjudicated recurrent ischemic stroke, my ocardi al infarcti on, 
or CV death by Day  90 
The incidence of adjudicated symptom atic recurrent stroke (including fatal and non-fatal) by 
Day 28
The incidence of the composite of unrecognized brain infarct ion assessed by MRI at Day 28
and MACE by  Day 90
Myocardial Infarct ionand cardi ovascular death will be adjudicated by the Clinical Events 
Adjudicat ion Committee (CEC) .  As the composite secondary  endpo ints are each defined in the 
list above, if a subject experiences any of these events, the subject will be counted as having 
experienced a co mposite event in the analysis.
4.3 Exploratory Endpoints
 
 
  
1.0
Approved
930113650
1.0
v

Statistical Analysis Plan CV006004
BMS -986141 par4
14  
4.4 Primary Safety Endpoint
The primary safety endpo int is incidence of a  composite of adjudicated major bleeding and 
adjudicated Clinically Relevant Non-Major (CRNM) bleeding during the treatm ent period.  If a 
subject experiences any of these events, the subject will be counted as having experience da 
composite event.
4.5 Additional Safety Endpoints
Addit ional safet y endpo ints include the incidence of adjudicated major bleeding events, all 
bleeding events, intracranial hemorrhage events, as well as the incidence of AEs and markedly 
abnor mal standard clinical laboratory  test resul ts.  As well, vital signs, ECG resul ts, physical 
exam findings, and certain renal  param eters and biomarkers, including estimated glom ular 
filtrat ion rate (eGFR) , Cystatin -C, NGAL, and KIM -1may be considered as additional safet y 
endpo ints.
5 SAMPLE SIZE AND POWE R
The primary efficacy endpo int of the study is the incidence of a  composite of symptomatic
ischemic stroke by  Day 28 and unrecognized brain infarction at Day  28. Sam ple size calculat ions
were performed for detecting a dose-response effect with the MCP -MOD methodol ogy using
simulat ions with the DoseFinding package in R4. Simulat ions of 1000 clinical trials were 
perform ed, assuming a true incidence for placebo of 14%, a maximum relative risk reduct ion of
30% forBMS -986141 8 mg relative to placebo, and relative reducti ons of 75% and 90% of the
maximum for the 0.8 and 4.8 m g doses, respect ively. Candidate models included an Emax model
and a logistic model.
Initially, rando mizat ion will be limited to the two lower doses of BMS-986141 (0.8 mg or4.8 
mg) or pl acebo in a 1:1:1 rati o until after the DMC review of safety  and laboratory data from  the
Day 28 study visit for at l east 10% of  planned total  subjects (approximately 132 subjects). If the
DMC recommends proceeding to inclusio n of the highest dose (8 mg), subsequent randomizat ion
will be in a 1:1:1:1 ratio. Based on the staggered rando mizat ion as shown in in the table below
and theassumpt ions above, the study  will have at least 80% power to demonstrate a dose-
response relationship, using a 1-sided type I error rate of 15%. A total sample size of 1312 
rando mized subjects accounts for about 5% of subjects without post- randomizat ion data .
Table 5 -
1: Randomization Targets
Placebo 0.8 mg 4.8 mg 8 mg
Prior to interim safety review by the DMC: 132 
subjects
(1:1:1 randomization ratio)44 44 44 0
Additional subjects randomized while interim safety 
reports are being generated and reviewed by the DMC 
(not included in the DMC safety interim analysis): 100 34 33 33 0
1.0
Approved
930113650
1.0
v

Statistical Analysis Plan CV006004
BMS -986141 par4
15Table 5 -1: Randomization Targets
Placebo 0.8 mg 4.8 mg 8 mg
subjects
(1:1:1 randomization ratio)
After interim safety review by DMC: 1081 subjects 270 270 270 270
Total: 1312 subjects 348 347 347 270
Note: Numbers shown for each treatment group are estimates based on randomization ratio.  Actual numbers could 
be slightly different based on randomization block size and rate of enrollment .
6 STUDY PERIODS, TREAT MENT REGIMENS AND PO PULATIONS FOR 
ANALYSES
6.1 Study Periods
As outlined in section 2.1, t he study will be conducted in two parts.
In Part 1 of the study , the treatm ent period will be 28 days. Part 2 of the study  will only be
initiated after regul atory  review of reports from 90-day nonclinical toxicology studies that are
currently ongoing. The treatm ent period in Part 2 will be 90 days. Subjects that are entered into 
Part 1 of the study  will not be allowed to enter into Part 2.
Periods for each part of the study include pre-treatment, on-treatm ent, and post-treatm ent.  
Schemat ics for each study  part are provi ded in Secti on 2.1.
6.2 Treatment Regimens
Study treatm ents will  be assigned according to the details provided in 
section 2.2 of thi s SAP.
6.3 Populations for Analyses
The analyses will use several populations as defined below.
1) All Enrolled Subjects : Includes all subjects who signed informed consent.
2)All Rando mized Subjects / Intent to Treat (ITT) Popul ation: Includes all subjects who were 
rando mized to a treatm ent, regardless of whether they received study  drug or not.  This 
popul ation will be analyzed according to the treatment assigned at randomizatio n.
3)All Evaluable Subjects : Includes All Rando mized Subjects asabove, excluding those 
subjects’ visits where rel evant protocol  deviat ions occurred, as defined in Sect ion 7.2.2.
4)All Treated Subjects : Includes all subjects who received at least one dose of study 
medicat ion.  This will be the primary popul ation used in safety analyses and will be analyzed 
according to the treatment assigned at randomizat ion, except in the following cases:
If a subject received the same incorrect treatm ent throughout the study  (until either Day 
28 or Day 90, or until discont inuat ion of the study  drug), then the subject will be 
analyzed based on the treatment received.
1.0
Approved
930113650
1.0
v
Statistical Analysis Plan CV006004
BMS -986141 par4
16If a subject received study  drug from mo re than one treatm ent group, and none of the 
admi nistrati ons were consistent with the assigned rando mized treatm ent group, then the 
subject will be analyzed based on the first treatment received.
5)Pharmacodynamic s(PD) Popul ation: A subset of the ITT Populat ion that includes subjects 
with at least one pharmacodynamic endpo int assessed following the first dose of BMS-
986141 .
6)Pharmacokinet ic (PK) Popul ation:Includes all subjects treated with BMS -986141 who also 
have at least one post -dose PK sam ple.  The Evaluable PK Popul ation is further defined as a 
subset of  the PK Popul ation including subjects wh o have adequate PK profiles on D ay 1.
7 STATISTICAL ANALYSES
SAS® versio n 9 or higher will be used for statistical analyses, tabulat ions and graphical 
presentations. The DoseFinding package for R (version 3.1.3orhigher) will also beused in the 
conduct of the mult iple co mpar isons modelling analyses .
7.1 General Methods
Descript ive summaries will be presented for continuous variables using number of subjects (N), 
mean, standard deviat ion (SD), median, minimum and maximum. Geometric mean and 
coefficient of variat ion (%CV) will also be presented for sample plasma concentrat ion-time data 
and PK parameters. Descript ive summaries for categori cal variables will utilize counts and 
percentages. 
Adverse events will be coded according to the most recent Medical Dictionary for Regulatory 
Activities (MedDRA) versi on.  Adverse events will be summarized according to the MedDRA 
coded Preferred Terms (PT) by System Organ Class (SOC) . Previous and conco mitant 
medicat ions will be coded using the WHO Drug Dict ionary version. 
Unless otherwise specified, baseline is defined as the last non-missing resul t with a  collection 
date-time prior to the date -time of the first active dose of study  medicat ion.
7.1.1 General Methods for Study Periods
Given the different planned study  treatment duratio ns between Part 1 (treatment duration of 28 
days) and Part 2 (treatment duration 90 days) and time at which randomizat ion will be extended 
to include the high dose of BMS-986141 (8 mg) following review of safety data by the DMC, 
select summaries will be tabulated by the following three applicable study  time periods with 
respect to study  part and study  phase :
Part 1, Phase A  (1A)
Part 2, Phase A  (2A)
Part 2, Phase B  (2B)
Summaries will also be tabulated forPart 2 overall, to include data from all subjects with a 
planned treatm ent duration of 90 days.  The following summaries will be tabulated as indicated 
above .
1.0
Approved
930113650
1.0
v
Statistical Analysis Plan CV006004
BMS -986141 par4
17Dem ographics
Baseline characterist ics
Relevant protocol deviat ions
Disposi tion
Concomitant medicat ions, including CYP3A4 inhibitor use
Study  drug exposure and compliance
Bleeding events
Adverse even ts, including overall AEs, SAEs, AEs leading to discont inuat ion, related AEs, 
and deaths
Abnorm al laboratory  resul ts, including renal bio markers
Abnorm al ECG resul ts
Out of range vital signs
7.1.2 General Methods for Efficacy Analyses
Generalized Mult iple Co mparison Modelling (gMCP -Mod)
To demonstrate the dose-response relationship between BMS -986141 treatm ent (including
placebo) andtheprimary  endpoint, the primary analysis will be based on a generalized Multiple 
Com parisons and Modeling (gMCP -Mod) analysis56.This analysis tests for a dose-response 
relationship, allowing for uncertaint y in the dose-response relationship through inclusio n of 
contrasts from multiplepre-specified candi date models to assess dose-response. If a dose-
response relationship exists, then fitted estimates for the incidence of the primary endpo int will 
be calculated in each of the treatm ent groups using the selected dose -response model s.
The gMCP -Mod procedure extends the MCP -Mod methodol ogy to 
non-continuous endpoints.  
This is accomplished by decoupling the dose-response model from the expected response 
through the use of an ANOVA style parameteri zation of the dose-response parameter.  For the 
binary endpo int used in this study , a logistic regressi on of  the event proporti on at each dose level 
will be used, following adjustment for study time period (1A, 2A, 2B) via the inclusio n of an 
additive covari ate.  After this first step, the mean parameter estimates from the logistic model 
and the corresponding covari ance matrix, both of which areon the logit scale, will then be used 
during the rest of the gMCP -Mod procedure.  Point estimates from the selected modelswill be 
displayed on the proportion scale in all statist ical outputs.
Candi date Model sand Mul tiple Test ing Procedure
There are two candidate models that will be considered for the primary  analysis.  These arean 
Emax model and a logistic model, where dose-response will be tested using dose levels of 0 
(placebo), 1, 2, and 2. 3(corresponding to 0.8 mg, 4.8 mg, and 8mg)7.
The MCP -Mod p rocedure requi res certain parameter estimates be pre-specified for the candidate 
models based on available inform ation in order to derive optimum contrast coefficients for 
testing the null hypothesis: that a dose -response does not exist in any of the candi date m odels.  It 
1.0
Approved
930113650
1.0
v
Statistical Analysis Plan CV006004
BMS -986141 par4
18is through testing this hypothesis that the model which best describes the dose-response 
relationship will be identified8.  The param eters used to determine the contrast for testing will 
assume a placebo event rate of 14% and maximum ri sk reducti on of 4.2%.  For the Em ax m odel, 
the requi red param eter estimates used will be1.0 for the dose corresponding to half of the 
maximum effect and 1.0 for a “Hill”parameter that determines the steepness of the model at the 
dose of half effect. For the logistic model, theseparam eter estimates used will be 1.0 for the dose 
corresponding to half effect and 0.1 for the parameter that determines the steepness of the curve.   
These pre -specified parameter estimates will remain fixed through the contrast test ing porti on of 
the gMCP -Mod procedure in order to preserve the ty pe I error.
The gMCP -Mod procedure for non-continuous endpoints diverges from the original MCP -Mod 
procedure in the calculati on of  the optim um contrast coefficients.  The gMCP -Mod methods tha t 
will be used to calculate the optimum contrast coefficients requi re the pre-specified model 
param eters from above along with the cov ariance matri x from the logistic regressi on in the first 
step.  In pract ice, since the covariance matrix in the first step is based on actual data, the 
optimum contrast coefficients are recalculated when the actual  data beco me available.  The 
param eter estimates for the candidate models, however, will remain fixed.
These optimal contrast coefficients follow the form given below, and will be recalculated as 
described using the DoseFinding package in R once the actual data are available.
     ∝       −  ′   1
1    1 
Where µmis the event rate on the logit scale based on the corresponding candidate model m 
(m=1, 2) at the specified dose levels, and S corresponds to the covari ance matrix from  the 
logistic regressio n on the actual data in the first step.
In order to demonstrate a dose-response relationship, the following global hypothesis will be 
tested :
H0:      µ ≥0 for all m {1, 2}
H1:      µ < 0 for at least one m {1, 2}
where µ is the true event rate on the l ogit scal e at the specified dose levels.
For each candidate model (m=1, 2), thecontrast test statistic (zm)is calculated as standardized 
linear combinations of the estimated event rate on the logit scale from the logistic regressio n
using the optimal contrast coefficients associ ated wi th that candi date m odel. 
A multiplicit y-adjusted critical value will be determi ned from the joint multivariate norm al 
distribut ion of the contrast test stati stics at the overall one-sided alpha level of 0.15 .  If eit her test 
statist ic that exceeds this crit ical value, a dose -response relat ionship will be demo nstrated.
Modelling and E stimat ion
The model for estimati on will be selected from among the two candi date models with a contrast 
test stati stic that is greater than or equal  to the multiplicit y-adjusted critical value.  If both 
1.0
Approved
930113650
1.0
v
Statistical Analysis Plan CV006004
BMS -986141 par4
19candidate models have such contrast test statistics, thenboth models will be empl oyed using a 
weighted averaging technique based on their relative Bayesian Information Criteria (BIC), for 
the purposes of estimation .  If neither candidate model has a contrast test statistic that is greater 
than or equal  to the multiplicit y-adjusted cri tical value, then the analysis will  end, indicat ing that 
a dose -response relat ionship cannot be established.
In this manner, the point estimates for the means will be generated from the selected model as 
described in the efficac y analyses in Sect ion 7.5.
7.2 Study Conduct
7.2.1 Accrual
The accrual pattern will be summari zed per country , invest igational site, and per month for all 
rando mized subjects. Enrollment date, randomizat ion date, first dosing date, coun try, 
investigat ional site will be presented in a by  subject list ing o f accrual.
7.2.2 Relevant Protocol Deviations
Relevant deviat ions from the study  protocol  will be documented and accounted for in presenting 
the data summaries, listings and descript ive statistical analyses. Any changes from planned 
protocol -specified analyse s will be defined in the SAP and reported in the CSR.   The relevant 
protocol  deviat ions are described in the table belo w.
Table 7.2.2 -1: List of Relevant Protocol Deviations
Number RPD Criteria
1 Subject randomized but not dosed
2 Error in treatment assignment (resulting in a subject receiving a treatment other than that 
assigned by the IVRS) during the first 28-day interval
3 Poor treatment compliance for either BMS -986141 o r ASA (compliance less than 80% or more 
than 120%) during first 28-day interval
4 Randomized subjects with history of atrial fibrillation (AF) other than transient AF related to 
cardiac surgery at enrollment (per Exclusion Criteria 1a from the protocol)
5 Randomized subjects with unrecognized or misdiagnosed intracranial hemorrhage (ICH) as 
determined by the central reader based on  the baseline study specific MRI (presence of type 1 or 
2 parenchymal hematoma )
6 Randomized subjects who took no dose of ASA or dose of ASA not within limits designated by 
the protocol for ≥ 5 consecutive days in the first 28 days of the treatment period
7 Randomized subjects who took oral anticoagulants or prohibited antiplatelet therapy, other than 
study medication, for > 2consecutive days during the first 28days of the treatment period
8 Randomized subjects that were treated with a strong CYP3A4 inhibitor for > 5 days during the 
first 28 days of the treatment perioda
a: CYP3A4 inhibitors will be defined in a separate file maintained by the study  team and will be classified as weak, 
moderate, or strong.
1.0
Approved
930113650
1.0
v
Statistical Analysis Plan CV006004
BMS -986141 par4
207.3 Study Population
All study  population summaries will be presented by treatm entand overall , as well as by study 
time period (1A, 2A, 2B) and for study  part 2.
7.3.1 Subject Disposition
Subject disposi tion will be listed for all enrolled subjects.  For subjects who are rando mized , the 
subject’s study  part, gender, age, race, consent date, randomization date, first and last dosing 
date, reason for treatm ent discont inuat ion, off-study  date, and reason for going off-study  will be 
listed.  For subjects who enroll, but are not treated, the subject’s gender, age, race, consent date, 
and reason for not entering the treatment period will be listed.
Summary  tables reflect ing the number of subjects enrolled, rando mized ,andtreated, reasons for 
not entering the treatment period, and number completingthe study  will be presented by 
treatm ent and study  time period (1A, 2A, 2B), and for study  part 2.
The number of subjects who do not completetreatm ent and also the number who do not 
complete the study , both overall and according to reasons for discont inuat ion, will also be 
summarized by treatment and study  time peri od (1A, 2A, 2B), and for study  part 2. .
7.3.2 Demographic and Baseline Characteristics
The fo llowing baseline characteri stics will be summarized by treatm ent group for all randomized 
subjects, overall, as well as by study  time period (1A, 2A, 2B), and for study  part 2. All baseline 
presentations will identify subjects with mi ssing measurements. 
Age (descript ive statist ics)
Age category  I, in years (<65, 65)
Age category  II, in y ears (<65, 65- <75, 75)
Gender (male, female)
Race (White, Black or Af rican American , Asian, American Indian  or Al aska Native, Native 
Hawaiian or Other pacific islander, Other)
Ethnicit y (Hispanic/Lat ino, Non Hispanic/Lat ino) for US subjects
Geographical Regio n (North America , Europe, Asia / Pacific)
Height, Weight , and BMI
Acute Ischemic Stroke at Entry   (Yes/No)
National Inst itutes of Healt h Stroke Score (NIHSS) at Baseline
High-risk Transient Ischemic Attack at Entry   (Yes/No)
Lacunar Infarct
Diabetes m ellitus (Yes/No)
Cigarette use (Yes/No)
Hypercho lesterol emia (Yes/No)
Hypertensio n (Yes/No)
BMI Category (<18, 18 -25, 25-30, 30- 35, >35)
1.0
Approved
930113650
1.0
v
Statistical Analysis Plan CV006004
BMS -986141 par4
21Vital signs
Time since onset of symptoms detected to rando mization
7.3.3 Medical History
General medical history  will be summarized by treatm ent and study  time period (1A, 2A, 2B), 
and for study  part 2.
7.4 Exte nt of Exposure
7.4.1 Administration of Study Therapy
The number of days onstudy  medicat ion received will be calculated as (date of first dose -date 
of last dose) + 1.  The days on study  medicat ion will be summarized for all treated subjects by 
treatm ent and study  time peri od (1A, 2A, 2B), and for study part 2 using descri ptive statistics as 
well as categorically  as given in the tabl e bel ow.
Table 7.4.1 -1: Extent of Exposure Categories for Summarization
Part 1 Exposure Categories Part 2 Exposure Categories
1 -7 days 1 -14 days
8 -14 days 15 -28 days
15 -21 days 28 -42 days
22 -28 days 43 -56 days
>28 days 57 -70 days
71 -84 days
> 85 days 
A by-subject listing of dosing of study medicat ion and a listing of batch numbers will be also 
provi ded.
7.4.2 Study Therapy Compliance
Com pliance wi th the protocol -specified study  therapy  will be summarized by  treatm ent group for 
all treated subjects by treatment and study  time period (1A, 2A, 2B), and for study  part 2 .  
For randomized study  therapy, the case report forms collect the number of doses taken perday.  
The kits dispensed for study  treatment are expected to contain 4 pills per day during Phase A of 
the study while the high dose arm is closed.  During Phase B, once the high-dose arm has 
opened, the number of pills dispensed to patients who are randomized from that point forward 
will be 2.  Thus, compliance with rando mized therapy  dosing will be calculated as given below
for each container of study  therapy :
%                              =100                                
(Phase A: 4 orPhase B: 2)
1.0
Approved
930113650
1.0
v
Statistical Analysis Plan CV006004
BMS -986141 par4
22Overall compliance will be calculated as the weighted average of the compliance for each 
container , wei ghted in prop ortion to the # of days each container was used.
Acet ylsalicylic acid (ASA) isan adjuvant therapy  that the protocol  requi res all  subjects receive at 
a total daily dose that is between 75mg and 162mg .  Overall compliance with ASA dosing will 
be calculated as given below:
%              =100                 ℎ                                    
(                −                 )+ 1
In addition, compliance will also be summar ized from  the first dose date to the lesser of the last 
date dosed and 28 days after the first date dosed.  The above calculat ions will be repeated using 
only data wi thin this t ime period.
Summaries of compliance will be presented according to the general methods for continuous 
variables as well as categori cally, according to the number and percentage of subjects with 
compliance in each of the following categories:
< 80%
  and  

7.4.3 Modifications of Study Therapy
The dosage of double blind study  medicat ion may not be increased or decreased during the
treatm ent period. Double blind study  medicat ion may be interrupted if treatm ent with prohibited
or restri cted concomitant therapies is needed as specified in section 3.4. 1 of the protocol .
7.4.4 Concomitant Medications
Concomitant medications, defined as medications other than study  medicat ions which are taken 
at any time on -treatm ent (i e, on or after the first d ay of study  therapy  and prior to the last dose of 
study  therapy ), will be coded using the WHO Drug Dictionary.
Concomitant medications will be summarized (subjects with any conco mitant medicat ion, 
subjects by medicat ion class and generic term) for all treated subjects.   Addit ionally, a separate, 
but similar summary of allconcomi tant medicat ions that are moderate CYP3A4 inhibitors will 
be created.
7.5 Efficacy
Adjudicated events will be the basis for the primary  and secondary analyses, includi ng imaging 
assessments from the Imaging Adjudicat ion Committee (IAC)and clinical assessments from the 
CEC.   All efficacy analyses will be conducted on the Intent- To-Treat (ITT) population.
7.5.1 Primary Efficacy Analysis
Using the general  methods for efficacy analyses described in 17, the observed incidence of the 
composite of symptom aticischemic stroke by
 Day 28 and unrecognized brain infarction assessed 
1.0
Approved
930113650
1.0
v
Statistical Analysis Plan CV006004
BMS -986141 par4
23by MRI at Day 28 will be summarized by treatm ent using thefitted model from the gMCP -Mod 
procedure. It should be noted that the selected model from gMCP-Mod will actually be a model 
for the l ogit of the incidence rate.  As a resul t, the point estimate will be converted and presented 
on the probabilit y scale by treatm ent.  
In addition, the raw proporti on of incidence within each treatm ent group and its associ ated 95% 
Clopper -Pearson CI will be presented . The relative risk reduct ion between each BMS -
986141 
arm and placebo and the associated 95% CIwill be present ed as well.  The form of the relative 
risk reducti on between each treatm ent group and placebo is given below.
              −             
             = 1 −             
             
7.5.1.1 Sensitivity Analyses
To assess the robustness of the primary efficacy analysis, additional sensi tivity analyses will be 
carried out using the fo llowing approaches:
Following the same procedure as the primary analysis, considering the All Evaluable 
Subjects populat ion in place of the All Rando mized Subjects populat ion. 
Aworst -case analysis that will repeat the primary analysis on the ITT p opulation where any 
missing information that is consequent ial to the evaluat ion of the primary endpo int will be 
considered as an ev ent.
7.5.1.2 Subgroup Analyses
All analyses described in this section will be perform ed on the ITT Popul ation. Table 7.5.1.2 -1
below shows the subgroups of interest f or analyses of  efficacy data.  If  the value of  the grouping 
variable cannot be determined for a subject, the subject will be excluded from the corresponding 
subgroup analysis.
Table 7.5.1.2 -1: Subgroups of Interest for Efficacy Assessments
Grouping Variable Subgroups
Event at entryAcute ischemic stroke
Transient ischemic attack
Time since onset of symptoms detected to 
randomization< 24 hours
24 -48 hours
Lacunar infarct at entryYes
No
Oxfordshire Community Stroke Project (OC SP) 
Subtype (only for stroke) at entryTotal Anterior Circulation Stroke (TAC)
Lacunar Stroke (LAC)
Partial Anterior Circulation Stroke (PAC)
Posterior Circulation Stroke (POC)
ABCD2aScore (only for TIA) at entry 4-5(moderate)
1.0
Approved
930113650
1.0
v
Statistical Analysis Plan CV006004
BMS -986141 par4
24Table 7.5.1.2 -1: Subgroups of Interest for Efficacy Assessments
Grouping Variable Subgroups
6-7(high)
Age< 65 y ears old
≥ 65 to < 75 years old
≥ 75 years old
GenderMale
Female
RaceWhite
Black or African American
Asian
Other
Geographic RegionNorth America
Europe
Asia / Pacific
aage, blood pressure, clinical features, duration, diabetes
7.5.2 Secondary Efficacy Analyses
Thesame approach used in the primary  analysis will  be repeated on the secondary  endpoints.
The incidence of major adverse cardi ovascular events (MACE) by Day 90, defined as a 
composite of adjudicated recurrent stroke, my ocardi al infarct ion, or CV death
The incidence of a co mposite of adjudicated recurrent ischemic stroke, my ocardi al infarcti on, 
or CV death by Day  90
The incidence of adjudicated symptom atic recurrent stroke (including fatal and non-fatal) by 
Day 28
The incidence of the composite of unrecogniz ed brain infarct ion assessed by MRI at Day 28 
and MACE by  Day 90
In addition, asequent ial testing procedure will be used for the primary and MACE endpo intsas 
described below . 
1)If a dose-response relationship is established for the primary endpo int at the one-sided 0.15 
level , then the primary  analysis will be repeated at a one -sided alpha l evel of 0.025 .
2)If this analysis at the one-sided 0.025 level also demonstrates a dose-response relationship, 
then the dose-response relationship for the MACE endpoint will be tested using a one-sided
alpha level  of 0.025.
Each of these sequent ial testing analyses will be performed.  Their interpretati on will be guided 
by the sequent ial testing procedure.
1.0
Approved
930113650
1.0
v
Statistical Analysis Plan CV006004
BMS -986141 par4
257.5.3 Other Efficacy Analyses
The primary analysis will be repeated forthe composi te endpoint o f recurrent ischemic stroke or 
any adjudicated arterial thrombotic events up to 90 days.   As well, the primary analysis will be 
repeated using each of its co mponents, individually, as the response variable.
Addit ionally , the following exploratory analyses may  be expl ored:
  
 
 
 
  
7.6 Safety Analyses
Analysis of all safety data will be conducted on all treated subjects and will follow the BMS 
guideline o f analysis of safet y data9.  Safet y will be summari zed f or each parameter by treatm ent 
group, as well as for all subjects receiving BMS -986141.   Summaries of the frequency of 
subjects experiencing certain events, such as adverse events, elevated labs or vital signs, or 
elevated ECGs, will be summarized by treatm ent and study  time period (1A, 2A, 2B), and for 
study  part 2.
The evaluat ion of safety is based onadjudicated bleeding events, clinical adverse events (AEs), 
vital signs, ECG resul ts, and clinical laboratory  resul ts.
All AEs will be coded and grouped into Preferred Term s (PT) by System  Organ Class (SOC), 
using the most current available version of Medical Dictionary for Regulatory  Activit ies 
(MedDRA). Summaries of AEs will use the version of MedDRA that is current at the time of 
database lock. All recorded adverse events will be listed and tabulated by SOC , PT, treatm ent 
and overall. Values for ECG s, vital signs, and clinical laboratory  test resul ts will be summarized 
by treatm ent. Abnormal resul tsfor ECG, vital signs and clinical laboratory  tests that falloutsi de 
the pre-specified criteria will also be listed and summarized. In addition, ECG readings will be 
evaluated by the Invest igator and abnormalit ies, if present, will be listed .
7.6.1 Major Bleeding and Clinically Relevant Non -Major Bleeding
The proporti on of  subjects wi th adjudicated bleeding events which occur on or after the first dose 
of study  treatm ent and wi thin 4days after the last dose of study  treatm entwill be summarized by 
treatm ent. Point estimates and 95% exact CIs for event rates of each of the below bleeding
endpo intswill be presented by treatment, together with point estimates and 95% exact CIs for the 
difference of event rates between each BMS -986141 arm and placebo.   The following bleeding 
endpo ints will be analyzed using these methods.
1.0
Approved
930113650
1.0
v

Statistical Analysis Plan CV006004
BMS -986141 par4
26The proporti on of subjects with the composite of adjudicated majo r bleeding and CRNM 
bleeding
The proportion of subjects with all reported bl eeding
The proportion of subjects with intracranial hemorrhage
All adjudicated bleeding events will be listed.  Inaddition, the proporti on of subjects with 
confirmed major bleeding or clinically relevant non-majo r bleeding events occurring during the 
treatm ent peri od will be summarized by treatment group for each of the following factors.
Stroke severit y (based on Na tional Inst itutes of Health Stroke Scale NIHSS) at study  entry
NIHSS Score of 0 (No stroke symptoms)
NIHSS Score of 1- 4 (Minor stroke)
NIHSS Score of 5- 15 (Moderate stroke)
Lacunar infarct at study  entry
Yes
No
7.6.2 Deaths
All reported deaths after a subject i s enrolled (i.e., has signed the informed consent) will be listed 
separately by subject.   Deaths will also be summari zed by treatment group according to whether 
the death was determined to be CV -related, not CV related, or unknown , following adjudicat ion.
7.6.3 Serious Adverse Events
All reported seri ous adverse events (SAEs) will be listed for all enrolled subjects .  A summary of 
SAEs occurring from the day of the first dose of study drug through 30 days following the last 
dose of study drug will also be provi ded for all treated subjects by SOC and PT for each 
treatm ent group. A separate summary o f SAEs related to study  drug will  also be provi ded.
7.6.4 Adverse Events
All AEs will be summarized by  SOCs and PTs for each treatment group and also listed .
Adverse events which occur on or af ter the first dose of study treatm ent and within 4days after 
the last dose of  study  treatm ent will be tabulated.  Events will be assigned to the study  treatm ent 
administered to the subject. The proporti on of subject shaving an adverse event will be 
calculated as the number of subjects experi encing the event, divided by the total number of 
subjects receiving study  treatm ent.
A high-level summary will be presented by treatment group that counts subjects experi encing 
anyof the f ollowing:
At least one AE
At least one related AE
1.0
Approved
930113650
1.0
v
Statistical Analysis Plan CV006004
BMS -986141 par4
27Deaths
At least one SAE
SAE l eading to di scont inuat ion of study  drug
AE leading to discontinuation of study  drug
The above summary will also be presented by treatm ent and study  time period (1A, 2A, 2B), and 
for study  part 2 .
All AE list ings will indicate the unique subject i dentifier, age, gender, current treatment, the date 
of onset, the date of resolution, day of onset relative to the start of treatment, action taken, 
investigator’s assessment ofseverit y and relationship to study drug. Addit ionallistings will be 
provi ded for adverse events leading to discont inuation ,serious adverse events, adverse events 
leading to death, and adverse events wi thout a recorded resol ution. Summaries of adverse ev ents 
will include adverse events, adverse events by intensity, adverse events leading to 
discontinuat ion,and adverse events by relationship.  
All adverse events will be further summarized according to dem ographic factors for each of the 
categori es given below:
Age category  I, in years (<65, 65)
Age category  II, in y ears (<65, 65- <75, 75)
Gender (male, female)
Race (White, Black or Af rican American, Asian, American Indian  or Al aska Native, Native 
Hawaiian or Other pacific islander, Other)
Where a subject has multiple adverse events within the level of summarizat ion in a single 
analysis period, the subject will only be counted once atthat levelof summarizat ionin the 
adverse event frequency  tables.
When a subject has the same adverse event , based on preferred termino logy, reported multiple 
times in a single analysis period, the following criteria, in order of precedence, will be used to 
select the event to be included in summary tables:
Relationship to study  medicat ion
Intensit y of event
When reporting adverse events by intensity, summary  tables will be provi ded based on the most 
intense event during the analysis period -independent of relationship to study  medicat ion.  
Similarly, where a subject has multiple adverse events within the level of summarizati on in a 
single analysis period, the subject will only be counted once at that l evel of  summarizat ion in the 
adverse event frequency  tables
7.6.5 Clinical Laboratory Evaluations
Summari esof laboratory test resul ts and the corresponding change from baseline by treatm ent 
and nominal visit will be providedfor those laboratory tests requi red at each study  visit as given 
in Table 5.3.7 -1 of the protocol.
1.0
Approved
930113650
1.0
v
Statistical Analysis Plan CV006004
BMS -986141 par4
28The criteria used for classifying laboratory  test results as markedly abnormal  will be listed. 
These criteria are provided in an appendix to this SAP.
Laboratory  results for subjects with any marked laboratory  abnorm ality (scheduled and 
unscheduled) will be listed. This listing will include all observat ions for the specific laboratory 
test and subject, not only  the marked laboratory  abnorm alities. The frequency  of subjects with 
any marked laboratory  abnormalit y will be presented by treatment and study  time period (1A, 
2A, 2B), and for study  part 2 . 
In addi tion to the analysis of standard laboratory  resul ts, separate analyses will focus specifically 
on renal param eters.   Renal biomarkers, including Cystatin -C, NGAL, and KIM -1 will be 
summarized according to the number and percentage of subjects in each treatment group with 
levels exceeding the upper limit of norm al (ULN) at each study visi t where labs are collected per 
protocol .  Additionally, estimated Glomerular Filtration Rate (eGFR) using the Modificat ion of 
Diet in Renal Disease formula (MDRD) will be summar ized at each visit by the mean, standard 
deviat ion, range, and median.
Urinalysis result s will also be summarized in the same manner as the laboratory  test resul ts.
7.6.6 Electrocardiograms
Summaries of ECG resul ts and the corresponding change from baseline by treatm ent will be 
provi ded for the screening , Day 28,and end of treatm ent visits.  The normalit y/abnorm ality of 
the ECG tracing, as determined by the invest igator, will be summarized using frequency tables 
on the number of subjects who have a norm al/abnorm al ECG tracing at Day 28 and at Day 90 
(Part 2 only).  A listing of subjects with Investigator ident ified ECG abnorm alities will also be 
provi ded.
7.6.7 Vital Signs
Vitalsign measurements (systolic BP, diastolic BP, heart rate, respi ratory  rate and body 
temperature) and thei r respect ive changes fro m baseline will be summarized by no minal visit and 
treatm ent group .
1.0
Approved
930113650
1.0
v
Statistical Analysis Plan CV006004
BMS -986141 par4
29The following criteria will be used to determine vital sign resul ts that are out a range, where 
changes fro m baseline are based on matched postural positions:
Table 7.6.7 -1: Out of Range Vital Signs Criteria
Vital Sign Measurement Criteria
Heart Rate(bpm) Value > 100 and change from baseline > 30, or
Value < 55 and change from baseline < -15
Systolic BP(mmHg) Value > 140 and change from baseline > 20, or
Value < 90 and change from baseline < -20
Diastolic BP(mmHg) Value > 90 and change from baseline > 10, or
Value < 55 and change from baseline < -10
Subjects with vital signs out of range will also be listed.
7.6.8 Physical Examination Findings
All physical examinat ion abnormal findings will be listed per subject and visit.
7.7 Pharmacokinetic Analyses
Analyses of pharmacokinet ics will be conducted on the Pharmacokinet ic Populati on.  
Pharmacokinet ics of BMS -986141 and BMT -162856 will be summarized with descriptive 
statist ics for Cmax, AUC(0 -24), C(24) after first dose, and C(24) on Day 28.
As well, apopulati on pharm acokinetic model will be devel oped to understand the 
pharmacokinet ics ofBMS -986141. The potenti al effect of covariates such as body  weight, age, 
gender, race, renal funct ion, liver function, and co-administration of other medicines on the 
pharmacokinet ics ofBMS -986141 will be explored in this analysis .  Details of this analysis and 
its resul ts will be reported in a separ ate docum ent.
7.8 Biomarker Analyses
 
 
 
 
 
1.0
Approved
930113650
1.0
v

Statistical Analysis Plan CV006004
BMS -986141 par4
30 
 
 
 
8 CONVENTIONS
Standard time windowing, imputation rules, and counting rules will be applied according to th e 
GBS Requirements for Statist ical Outputs10.  Unl ess otherwi se defined, baseline is defined as the 
last non -missing value prior to the first dose of study  drug.
8.1 Decimal Places
The number of decimal places displayed in all listings will be determined by the number of 
decimal places in the raw data. 
Unless otherwi se specified, minimum and maximum  will be reported to the precisi on as the data 
collected, one m ore decimal place for the m ean and m edian, and two m ore decimal places for the 
standard deviat ion.  The adjusted geom etric mean, geom etric mean ratio and the l ower and upper 
limits of confidence interval will be displayed to three decimal places.
8.2 Pharmacokinetic Summaries
Handling of Non -Quant ifiable Concentrations 
For the summaries of plasma concentrati on-time data, concentrati ons that are less than the lower 
limit of quant ificat ion (LLOQ) shoul d be displayed as “< LLOQ” in the list ings and be treated as 
missing in summary  tables and pl ots.  
Summary statistics for PD -concentrati ons will be calculated by imput ing values less than LLOQ 
as ½ * LLOQ.   
8.3 Day Ranges for Analysis of Time Points
Subjects do not al ways adhere stri ctly to the visi t schedule timing in the protocol . Theref ore, the 
designation of visits for analysis of safety  outc ome measures during the treatm ent peri od will be 
based on the day of the start of study medicati on (Day  1). The day ranges for the analyses of 
laboratory , electrocardi ogram  (ECG) and vital sign measurements are defined in the following 
tables.
1.0
Approved
930113650
1.0
v

Statistical Analysis Plan CV006004
BMS -986141 par4
31Table 8.3-1: Analysis Windows for Laboratory Parameters & Vital Signs (P art 1)
Visit Name Lower Limit
(Study Day)Upper Limit
(Study Day)
Day 1 1 1*
Day of Hospital Discharge 2 10
Day 28 11 N/A
* Pre -dose
Table 8.3-2: Analysis Windows for Laboratory Parameters & Vital Signs (Part 2)
Visit Name Lower Limit
(Study Day)Upper Limit
(Study Day)
Day 1 1 1*
Day of Hospital Discharge 2 10
Day 28 11 42
Day 56 43 68
Day 90 69 N/A
* Pre -dose
Table 8.3-3: Analysis Windows for ECG Results
Visit Name Lower Limit
(Study Day)Upper Limit
(Study Day)
Day 28 264a
Day 90a 65 N/A
a: Day 90 visit will only be conducted for subjects in Part 2 of the study.  Subjects in Part 1 of the study will only 
have a Day  28 ECG scheduled after beginning treatment, with no applicable upper limit to the analysis window.
8.4 Multiple Measurements
Laboratory  Measurements
For tabul ations of changes from baseline or shift analyses, if multiple laboratory  measurements 
are obtained within the same visit window , then the measurement obtained on the day closest to 
the target day for that visit window will be used; in the case of a tie, the measurement obtained 
on the earlier day  will be used in the analyses.
For tabul ations of incidence o f marked abnormalit ies (e.g. ALT > 3xULN), if mult iple laboratory 
measurements are obtained within the same visit window , then the wors t measurement wi thin the
visit window will be used.
1.0
Approved
930113650
1.0
v
Statistical Analysis Plan CV006004
BMS -986141 par4
32Vital Signs and ECGs
If multiple vital sign or ECG measurements are o btained within the same visit window , then the 
measurement obtained on the day closest tothe target day for thatvisit window will be used; in 
the case of a tie, the measurement obtained on the earlier day  will be used in the analyses.
9 CONTENT OF REPORTS
Statistical components for the clinical study  report will be based on the content of  this statistical 
analysis plan (SAP). Pharmacokinet ic and exploratory  biomarker resul ts may be reported 
separately .
Details of the tables, listings, and figures to be prepared for the final CSR will be included in a 
study -specific Data Presentation Plan (DPP).
1.0
Approved
930113650
1.0
v
APPENDIX 1 MARKED ABNORMALITY C RITERIA FOR LAB ORATORY
TEST RESULTS - CONVENTIONAL (US) UN ITS
Clinical Laboratory 
VariablesUnits Low MA Criterion High MA Criterion
HEMATOLOGY
Hemoglobin g/dL> 2 g/dl decrease compared to pre -
dose or value ≤ 8 g/dl
Hematocrit % < 0.75 x pre -dose
Erythrocy tesx106
cells/µL< 0.75 x pre -dose
Platelet Countx109
cells/µL< 100,000/mm3(or < 100x 109
cells/L)
Leukocytesx103
cells/µL< 0.75 x LLN, or
if pre -dose < LLN then use < 0.8 x 
pre-dose
if pre -dose > ULN then use < LLN> 1.25 x ULN, or
if pre -dose < LLN then use > ULN
if pre-dose > ULN then use > 1.2 x 
pre-dose
Neutrophils (absolute)x103
cells/µL< 1.0 x 103cells/µL
Neutrophils + Bands 
(absolute)x103
cells/µL< 1.0 x 103cells/µL
Eosinophils (absolute)x103
cells/µL> 0.750 x 103cells/µL
Basophils (absolute)x103
cells/µL> 400/mm3(or > 0.4 x 103
cells/µL)
Monocytes (absolute)x103
cells/µL> 2000/mm3(or > 2 x 103
cells/µL)
Lymphocy tes (absolute)x103
cells/µL< 0.750 x 103cells/µL > 7.50 x 103cells/µL
LIVER/KIDNEY
Alkaline Phosphatase U/L > 2 x ULN
Aspartate 
AminotransferaseU/L > 3 x ULN
Alanine 
AminotransferaseU/L > 3 x ULN
Bilirubin, Total mg/dL > 2 x ULN
Bilirubin, Direct mg/dL > 1.5 x ULN
Blood Urea Nitrogen mg/dL > 2 x ULN
Creatinine mg/dL > 1.5 x ULN
ELECTROLYTES
1.0
Approved
930113650
1.0
v
Statistical Analysis Plan CV006004
BMS -986141 par4
34APPENDIX 1 MARKED ABNORMALITY C RITERIA FOR LAB ORATORY
TEST RESULTS - CONVENTIONAL (US) UN ITS
Clinical Laboratory 
VariablesUnits Low MA Criterion High MA Criterion
Sodium, Serum mEq/L< 0.95 x LLN, or
if pre -dose < LLN then use < 0.95 
x pre -dose
if pre -dose > ULN then use < LLN> 1.05 x ULN, or
if pre -dose < LLN then use > ULN
if pre -dose > ULN then use > 1.05 
x pre -dose
Potassium, Serum mEq/L< 0.9 x LLN, or
if pre -dose < LLN then use < 0.9 x 
pre-dose
if pre -dose > ULN then use < LLN> 1.1 x ULN, or
if pre -dose < LLN then use > ULN
if pre -dose > ULN then use > 1.1 x 
pre-dose
Chloride, Serum mEq/L< 0.9 x LLN, or
if pre -dose < LLN then use < 0.9 x 
pre-dose
if pre -dose > ULN then use < LLN> 1.1 x ULN, or
if pre -dose < LLN then use > ULN
if pre -dose > ULN then use > 1.1 x 
pre-dose
Calcium, Total mg/dL< 0.8 x LLN, or
if pre -dose < LLN then use < 0.75 
x pre -dose
if pre -dose > ULN then use < LLN> 1.2 x ULN, or
if pre -dose < LLN then use > ULN
if pre -dose > ULN then use > 1.25 
x pre -dose
Bicarbonate mEq/L< 0.75 x LLN, or
if pre -dose < LLN then use < 0.75 
x pre -dose
if pre -dose > ULN then use < LLN> 1.25 x ULN, or
if pre -dose < LLN then use > ULN
if pre -dose > ULN then use > 1.25 
x pre -dose
Phospho rus mg/dLIf pre -dose = missing then use < 
0.85 x LLN
If LLN ≤ pre -dose ≤ ULN then use 
< 0.85 x LLN
If pre -dose < LLN then use < 0.85 
x pre -dose
If pre -dose > ULN then use < LLNIf pre -dose = missing then use > 
1.25 x ULN
If LLN ≤ pre-dose ≤ ULN then use 
> 1.25 x ULN
If pre -dose > ULN then use > 1.25 
x ULN
If pre -dose < LLN then use > ULN
OTHER CHEMISTRY
Lactate Dehydrogenase 
(LDH)U/LIf pre -dose = missing then use > 
1.25 x ULN
If pre -dose ≤ ULN then use > 1.25 
x ULN
If pre-dose > ULN then use > 1. 5 
x pre -dose
Total Protein g/dL< 0.9 x LLN, or
if pre -dose < LLN then use 0.9 x 
pre-dose
if pre -dose > ULN then use < LLN> 1.1 x ULN, or
if pre -dose < LLN then use > ULN
if pre -dose > ULN then use 1.1 x 
pre-dose
Albumin g/dLIf pre -dose = missing then use < 
0.9 x LLN
1.0
Approved
930113650
1.0
v
Statistical Analysis Plan CV006004
BMS -986141 par4
35APPENDIX 1 MARKED ABNORMALITY C RITERIA FOR LAB ORATORY
TEST RESULTS - CONVENTIONAL (US) UN ITS
Clinical Laboratory 
VariablesUnits Low MA Criterion High MA Criterion
if pre -dose ≥ LLN then use < 0.9 x 
LLN
If pre -dose < LLN then use < 0.9 x 
pre-dose
Glucose, Serum Fasting mg/dL< 0.8 x LLN, or
if pre -dose < LLN then use < 0.8 x 
pre-dose
if pre -dose > ULN then use < LLN>1.5 x ULN, or
if pre -dose < LLN then use > ULN
if pre -dose > ULN then use > 2.0 x 
pre-dose
Uric Acid mg/dL> 1.5 x ULN, or
if pre -dose > ULN then use > 2 x 
pre-dose
URINALYSIS
Glucose Urine N/Aif missing pre -dose then use 2, or
if value 4, or
if pre -dose = 0 or 0.5 then use 2, 
or
if pre -dose = 1 then use 3, or
if pre -dose = 2 or 3 then use 4
Protein, Urine N/AIf missing pre -dose then use 2, or
if value 4, or
if pre -dose = 0 or 0.5 then use 2, 
or
if pre -dose = 1 then use 3, or
if pre -dose = 2 or 3 then use 4
Blood, Urine N/AIf missing pre -dose then use 2, or
if value 4, or
if pre -dose = 0 or 0.5 then use 2, 
or
if pre -dose = 1 then use 3, or
if pre -dose = 2 or 3 then use 4
Leukocyte Esterase, 
UrineN/AIf missing pre -dose then use 2, or
if value 4, or
if pre -dose = 0 or 0.5 then use 2, 
or
if pre -dose = 1 then use 3, or
if pre -dose = 2 or 3 then use 4
RBC, Urine hpfIf missing pre -dose then use 2, or
if value 4, or
1.0
Approved
930113650
1.0
v
Statistical Analysis Plan CV006004
BMS -986141 par4
36APPENDIX 1 MARKED ABNORMALITY C RITERIA FOR LAB ORATORY
TEST RESULTS - CONVENTIONAL (US) UN ITS
Clinical Laboratory 
VariablesUnits Low MA Criterion High MA Criterion
if pre -dose = 0 or 0.5 then use 2, 
or
if pre -dose = 1 then use 3, or
if pre -dose = 2 or 3 then use 4
WBC, Urine hpfIf missing pre -dose then use 2, or
if value 4, or
if pre -dose = 0 or 0.5 then use 2, 
or
if pre -dose = 1 then use 3, or
if pre -dose = 2 or 3 then use 4
1.0
Approved
930113650
1.0
v
Statistical Analysis Plan CV006004
BMS -986141 par4
37APPENDIX 2 MARKED ABNORMALITY C RITERIA FOR LAB ORATORY
TEST RESULTS -- SI UNITS
Clinical Laboratory 
VariablesUnits Low MA Criterion High MA Criterion
HEMATOLOGY
Hemoglobin g/L> 20 g/l decrease compared to 
pre-dose or value ≤g/l
Hematocrit Vol < 0.75 pre -dose
Erythrocy tes x1012c/L < 0.75 pre -dose
Platelet Count x109cells/L < 100 x109cells/L
Leukocytes x109cells/L< 0.75 x LLN, or
if pre -dose < LLN then use < 
0.8 x pre -dose
if pre -dose > ULN then use < 
LLN> 1.25 x ULN, or
if pre -dose < LLN then use > ULN
if pre -dose > ULN then use > 1.2 x 
pre-dose
Neutrophils (absolute) x109cells/L < 1.0 x 109cells/L
Neutrophils + Bands 
(absolute)x109cells/L < 1.0 x 109cells/L
Eosinophils (absolute) x109cells/L > 0.750 x 109cells/L
Basophils (absolute) x109cells/L > 0.4 x 109cells/L
Monocytes (absolute) x109cells/L > 2 x 109cells/L
Lymphocy tes (absolute) x109cells/L < 0.750 x 103cells/µL > 7.50 x 109cells/L
LIVER/KIDNEY
Alkaline Phosphatase U/L > 2 x ULN
Aspartate 
AminotransferaseU/L > 3 x ULN
Alanine 
AminotransferaseU/L > 3 x ULN
Bilirubin, Total umol/L > 2 x ULN
Bilirubin, Direct umol/L > 1.5 x ULN
Blood Urea Nitrogen umol/L > 2 x ULN
Creatinine umol/L > 1.5 x ULN
ELECTROLYTES
Sodium, Serum mmol/L< 0.95 x LLN, or
if pre -dose < LLN then use < 
0.95 x pre -dose
if pre -dose > ULN then use < 
LLN> 1.05 x ULN, or
if pre -dose < LLN then use > ULN
if pre -dose > ULN then use > 1.05 
x pre -dose
1.0
Approved
930113650
1.0
v
Statistical Analysis Plan CV006004
BMS -986141 par4
38APPENDIX 2 MARKED ABNORMALITY C RITERIA FOR LAB ORATORY
TEST RESULTS -- SI UNITS
Clinical Laboratory 
VariablesUnits Low MA Criterion High MA Criterion
Potassium, Serum mmol/L< 0.9 x LLN, or
if pre-dose < LLN then use < 
0.9 x pre -dose
if pre -dose > ULN then use < 
LLN> 1.1 x ULN, or
if pre -dose < LLN then use > ULN
if pre -dose > ULN then use > 1.1 x 
pre-dose
Chloride, Serum mmol/L< 0.9 x LLN, or
if pre -dose < LLN then use < 
0.9 x pre -dose
if pre-dose > ULN then use < 
LLN> 1.1 x ULN, or
if pre -dose < LLN then use > ULN
if pre -dose > ULN then use > 1.1 x 
pre-dose
Calcium, Total mmol/L< 0.8 x LLN, or
if pre -dose < LLN then use < 
0.75 x pre -dose
if pre -dose > ULN then use < 
LLN> 1.2 x ULN, or
ifpre-dose < LLN then use > ULN
if pre -dose > ULN then use > 1.25 
x pre -dose
Bicarbonate mmol/L< 0.75 x LLN, or
if pre -dose < LLN then use < 
0.75 x pre -dose
if pre -dose > ULN then use < 
LLN> 1.25 x ULN, or
if pre -dose < LLN then use > ULN
if pre -dose > ULN then use > 1.25 
x pre -dose
Phospho rus mmol/LIf pre -dose = missing then use 
< 0.85 x LLN
If LLN ≤ pre -dose ≤ ULN then 
use < 0.85 x LLN
If pre -dose < LLN then use < 
0.85 x pre -dose
If pre -dose > ULN then use < 
LLNIf pre -dose = missing then use > 
1.25 x ULN
If LLN ≤ pre -dose ≤ ULN then use 
> 1.25 x ULN
If pre -dose > ULN then use > 1.25 
x ULN
If pre -dose < LLN then use > ULN
OTHER CHEMISTRY
Lactate Dehydrogenase 
(LDH)U/LIf pre -dose = missing then use > 
1.25 x ULN
If pre -dose ≤ ULN then use > 1.25
x ULN
If pre -dose > ULN then use > 1. 5 
x pre -dose
Total Protein g/L< 0.9 x LLN, or
if pre -dose < LLN then use 0.9 
x pre -dose
if pre -dose > ULN then use < 
LLN> 1.1 x ULN, or
if pre -dose < LLN then use > ULN
if pre -dose > ULN then use 1.1 x 
pre-dose
Albumin g/L If pre -dose = missing then use 
1.0
Approved
930113650
1.0
v
Statistical Analysis Plan CV006004
BMS -986141 par4
39APPENDIX 2 MARKED ABNORMALITY C RITERIA FOR LAB ORATORY
TEST RESULTS -- SI UNITS
Clinical Laboratory 
VariablesUnits Low MA Criterion High MA Criterion
< 0.9 x LLN
if pre -dose ≥ LLN then use < 
0.9 x LLN
If pre -dose < LLN then use < 
0.9 x pre -dose
Glucose, Serum Fasting mmol/L< 0.8 x LLN, or
if pre -dose < LLN then use < 
0.8 x pre -dose
if pre -dose > ULN then use < 
LLN> 1.5 x ULN, or
if pre -dose < LLN then use > ULN
if pre -dose > ULN then use > 2.0 x 
pre-dose
Uric Acid mmol/L> 1.5 x ULN, or
if pre -dose > ULN then use > 2 x 
pre-dose
URINALYSIS
Glucose Urine N/AIf missing pre -dose then use 2, or
if value 4, or
if pre -dose = 0 or 0.5 then use 2, 
or
if pre -dose = 1 then use 3, or
if pre -dose = 2 or 3 then use 4
Protein, Urine N/Af missing pre -dose then use 2, or
if value 4, or
if pre -dose = 0 or 0.5 then use 2, 
or
if pre -dose = 1 then use 3, or
if pre -dose = 2 or 3 then use 4
Blood, Urine N/AIf missing pre -dose then use 2, or
if value 4, or
if pre -dose = 0 or 0.5 then use 2, 
or
if pre -dose = 1 then use 3, or
if pre -dose = 2 or 3 then use 4
Leukocyte Esterase, 
UrineN/AIf missing pre -dose then use 2, or
if value 4, or
if pre -dose = 0 or 0.5 then use 2, 
or
if pre -dose = 1 then use 3, or
if pre -dose = 2 or 3 then use 4
1.0
Approved
930113650
1.0
v
Statistical Analysis Plan CV006004
BMS -986141 par4
40APPENDIX 2 MARKED ABNORMALITY C RITERIA FOR LAB ORATORY
TEST RESULTS -- SI UNITS
Clinical Laboratory 
VariablesUnits Low MA Criterion High MA Criterion
RBC, Urine hpfIf missing pre -dose then use 2, or
if value 4, or
if pre -dose = 0 or 0.5 then use 2, 
or
if pre -dose = 1 then use 3, or
if pre -dose = 2 or 3 then use 4
WBC, Urine hpfIf missing pre -dose then use 2, or
if value 4, or
if pre -dose = 0 or 0.5 then use 2, 
or
if pre -dose = 1 then use 3, or
if pre -dose = 2 or 3 then use 4
1.0
Approved
930113650
1.0
v
10 REFERENCES
1Geeganage, C. M., et al. Dual or mono antiplatelet therapy for patients with acute 
ischemicstroke or transient ischemic attack: a system atic review and meta -analysis of 
rando mized controlled trials. Stroke, 2012; 43: p. 1058 -1066.
2International Stroke Trial Collaborative Group. The Internat ional Stroke Trial (IST): a 
rando mised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients 
with acute is chemic stroke. The Lancet, 1997; 349: p. 1569 -1581.
3Sandercock PAG, Counsell C, TsengMC, Cecconi  E.Oral  antiplatelet therapy  for acute 
ischaemic stroke. Cochrane Database of Systemat ic Reviews 2014, Issue 3. Art. No.: 
CD000029. DOI: 10.1002/14651858.CD0 00029.pub3.
4Bornkam p B, Pinheiro J, Bretz F. DoseFinding: planning and analyzing dose finding 
experiments. R package, http://www.cran.rproject. org/web/packages/DoseFinding/.
5Bretz F, Pinheiro JC, Branson M. Combining multiple com parisons and modelin g techniques 
in dose -response studies. Bio metrics 2005; 61:738–748.
6Pinheiro J, Bornkam p B, Glimm E, Bretz F. Model -based dose finding under model 
uncertaint y using general parametric models. Statistics in Medicine 2014; 33:1646 -1661.
7Bornkam p B, Pinheiro J, Bretz F. DoseFinding: planning and analyzing dose finding 
experiments. R package, http://www.cran.r -project.org/web/packages/DoseFinding/.
8Bornkam p B, Pinheiro J, Bretz F.  MCPMod: An R Package for the Design and Analysis of 
Dose -Finding Studie s. Journal  of Statistical Software, February  2009; Vol ume 29, Issue 7.
9CT SOP 109, Analysis of Safety Data. Bristol-Myers Squibb Research and Devel opment, 
September 2010.
10Bristol-Myers -Squibb Global Biometri cs Sciences General Requi rements for Statist ical 
Outputs, Revisio n 1.8.5, 06 -Nov
-2013.
1.0
Approved
930113650
1.0
v